LEBANON, N.H., April 15, 2026 /PRNewswire/ -- Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, congratulates GSK plc for recently ...
ZYCUBOapproved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 mi ...
Cutaneous Squamous Cell Carcinoma (cSCC) Market · GlobeNewswire Inc. The cutaneous squamous cell carcinoma (cSCC) market is set for notable expansion, with the market size anticipated to increase from ...
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 ...
NCCN guideline updates for CSCC emphasize immunotherapy as a cornerstone across disease stages, expanding its role from advanced disease into neoadjuvant and adjuvant settings. Recent updates to the ...
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] Technology appraisal guidance Cosibelimab for treating advanced cutaneous squamous ...
The acquisition of Checkpoint Therapeutics, Inc. (“Checkpoint”) by Sun Pharma generated meaningful upfront capital and established a long-term royalty stream from UNLOXCYT™ (cosibelimab-ipdl), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results